SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ANRG -- Anergen -- new CEO big chance ?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Chris G. who wrote (43)10/12/1997 12:50:00 AM
From: Cacaito   of 123
 
Immunex's Embrel blocks TNF receptors in the joints and decrease inflamatory damage.

Anergen's RA AnervaX is a synthetic peptide to induce antibodies against the inmune cells which wrongly are attaking the body's own joints.

It is a different mechanism, Embrel is proven. RA AnervaX is on type II trials.

Next month Anergen is expected to present results at the annual meeting of the American College of Rheumatology.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News